肿瘤药学2025，Vol.15Issue(4)：444-454,11.DOI:10.3969/j.issn.2095-1264.2025.04.02
抗体偶联药物在乳腺癌精准治疗中的创新靶点与多策略转化研究进展
Advances in innovative targets and multi-strategy translational research of antibody-drug conjugates for precision therapy of breast cancer
摘要
Abstract
Antibody-drug conjugates(ADCs)represent a paradigm-shifting advancement in breast cancer therapy through their trinity design paradigm combining target-specific antibodies,chemical linkers,and cytotoxic payloads,en-abling tumor-selective cytotoxicity while minimizing systemic toxicity.Currently,three ADCs have received regulatory approval for breast cancer treatment:trastuzumab emtansine(T-DM1)and trastuzumab deruxtecan(DS-8201a)targeting human epidermal growth factor receptor 2(HER2),alongside sacituzumab govitecan(SG)directed against trophoblast cell-surface antigen 2(TROP2).This review systematically examines emerging developments in ADC technology,includ-ing novel target diversification strategies,bispecific antibody engineering innovations,and dual-drug optimization meth-odologies.Through comprehensive analysis of translational research progress,we elucidate the evolving role of advanced ADCs in precision oncology and provide evidence-based guidance for their clinical implementation in breast cancer management.关键词
抗体偶联药物/乳腺癌/精准治疗/创新靶点/多策略转化Key words
Antibody-drug conjugate/Breast cancer/Precision therapy/Innovative targets/Multi-strategy translation分类
医药卫生引用本文复制引用
马艺文,李晓睿,姜翠,鄂颖,蒋雷,刘军,孙涛..抗体偶联药物在乳腺癌精准治疗中的创新靶点与多策略转化研究进展[J].肿瘤药学,2025,15(4):444-454,11.基金项目
辽宁省重点研发项目(2024JH2/102500058) （2024JH2/102500058）
沈阳市科学技术计划公共卫生研发专项(22-321-31-04) （22-321-31-04）
辽宁省肿瘤医院"肿瘤学+"项目(2024-ZLKF-04) （2024-ZLKF-04）
辽宁省博士启动联合基金项目(2023-BSBA-211). （2023-BSBA-211）
